Application of in Vivo Splitting Technique in Adult Liver Transplantation
NCT ID: NCT06925828
Last Updated: 2025-04-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
500 participants
OBSERVATIONAL
2021-01-01
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Liver Protection of RIPC in Pediatric Living Donor Liver Transplantation
NCT02830841
Ischemic Preconditioning of Liver in Cadaver Donors
NCT00245830
To Compare the Outcome of Temporary Portocaval Shunt During Recipient Hepatectomy Versus No Shunt in Adult Elective Live Donor Liver Transplantation.
NCT05385120
Allogenic Bone Marrow Stem Cells Transplantation in Patients With Liver Cirrhosis
NCT01223664
The Effect of Remote Ischemic Preconditioning in Living Donor Hepatectomy
NCT03386435
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
SLT group
Adult recipients who underwent split liver transplantation
No intervention
No intervention
WLT group
Adult recipients who underwent whole liver transplantation
No intervention
No intervention
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
No intervention
No intervention
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. age of 18-60 years;
2. BMI of 19-28 kg/m2;
3. hemodynamic stability or use of a single vasoactive drug with a small dosage (norepinephrine ≤ 0.1 μg/kg/min or dopamine ≤ 5 μg/kg/min);
4. liver steatosis ≤ 10%;
5. liver functional indicators (ALT, AST, total bilirubin quantification) ≤ 3 times the normal value;
6. blood sodium ≤ 160 mmol/L;
For the SLT recipients
1. Patients who had registered in the China Organ Transplant Response Systems.
2. Initial liver transplantation.
3. Graft-to-Recipient Weight Ratio (GRWR) ≥ 1%.
Exclusion Criteria
1. uncontrollable infection
2. significant vascular and biliary variation.
For the recipients
1. Severe portal hypertension.
2. Significant vascular variation.
16 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ningbo Medical Center Lihuili Hospital
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
lucaide
Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ningbo Medical Centre Lihuili Hospital
Ningbo, Zhejiang, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CT2025-LHL-OBS1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.